Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It also has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Generation 3 or Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
企業コードNXLIW
会社名Nexalin Technology Inc
上場日Sep 16, 2022
最高経営責任者「CEO」Mr. Mark White
従業員数- -
証券種類Company Warrant
決算期末- -
本社所在地1776 Yorktown
都市HOUSTON
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号77056
電話番号18322600222
ウェブサイトhttps://nexalin.com
企業コードNXLIW
上場日Sep 16, 2022
最高経営責任者「CEO」Mr. Mark White
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし